Industry Documents Library
#FromTheArchives This #Insys MOOP (maximum out of pocket) flowchart illustrates their Reimbursement Center’s work to push prior authorization (PA) for Subsys through commercial #insurance and #Medicare. #opioids #fentanyl https://www.industrydocuments.ucsf.edu/opioids/docs/#id=fgmy0281
Industry Documents Library

Oct 9, 2023 at 1:26pmWeb
Show threadIndustry Documents LibraryOct 9, 2023
The “vast majority of patients will have access to Subsys at no cost when HCP (healthcare provider) opts-in to IRC program.” #opioids #fentanyl
Show threadIndustry Documents LibraryOct 9, 2023
“The United States also alleged that Insys improperly encouraged physicians to prescribe Subsys for patients who did not have cancer, and lied to insurers about patients’ diagnoses in order to obtain reimbursement for Subsys prescriptions that had been written for Medicare and TRICARE beneficiaries.” https://www.justice.gov/opa/pr/opioid-manufacturer-insys-therapeutics-agrees-enter-225-million-global-resolution-criminal
Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations

Opioid manufacturer Insys Therapeutics agreed to a global resolution to settle the government’s separate criminal and civil investigations, the Department of Justice announced today. As part of the criminal resolution, Insys will enter into a deferred prosecution agreement with the government, Insys’s operating subsidiary will plead guilty to five counts of mail fraud, and the company will pay a $2 million fine and $28 million in forfeiture. As part of the civil resolution, Insys agreed to pay $195 million to settle allegations that it violated the False Claims Act. Both the criminal and civil investigations stemmed from Insys’s payment of kickbacks and other unlawful marketing practices in connection with the marketing of Subsys. Insys’s drug Subsys is a sublingual fentanyl spray, a powerful, but highly addictive, opioid painkiller. In 2012, Subsys was approved by the Food and Drug Administration for the treatment of persistent breakthrough pain in adult cancer patients who are already receiving, and tolerant to, around-the-clock opioid therapy.